For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat hemophilia A. The Cambridge, Massachusetts-based biotech is closing “following ...

With a move into Lilly Gateway Labs in Boston’s Seaport District, privately held Tevard Biosciences Inc. is ramping up development of its transfer RNA (tRNA)-based therapies to cure everything from ...

Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic. The Massachusetts-based outfit has laid off ...